Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868073 | 0.86 | KMT2A (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28657953 | 0.84 | KCNQ3 (0.53) | KDM4EGAAHPGDALDH1A1NPC1 | |
| SCHEMBL13720824 | 0.84 | TSHR (0.53) | LMNAKDM4EGAAKMT2AALDH1A1 | |
| SCHEMBL8360615 | 0.84 | MLYCD (0.46) | GAAALDH1A1MAPT | |
| Ethyl Nicotinate SCHEMBL29126551 | 0.82 | ALDH1A1 (0.54) | LMNAKDM4EKMT2AHPGDALDH1A1 | |
| SCHEMBL10276146 | 0.82 | NPC1 (0.46) | CYP1A2KDM4EGAAKMT2AHPGD | |
| SCHEMBL1317978 | 0.82 | MAPK1 (0.59) | CA12CA1CA2CA7CA9 | |
| Ethyl Nicotinate SCHEMBL29126564 | 0.82 | ALDH1A1 (0.53) | LMNACYP1A2CYP3A4KDM4EGAA | |
| SCHEMBL27795045 | 0.81 | POLB (0.43) | GAANPC1RAB9ASMN1; SMN2KCNQ3 | |
| SCHEMBL3590555 | 0.80 | KCNQ3 (0.40) | KDM4EGAAHPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054431-A1 | BENZO-FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| EP-4114829-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-01-11 | — | — | EP | disclosed |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-09 | — | — | US | disclosed |
| US-20090275618-A1 | 1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090275618-A1 | 1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-11-05 | — | — | US | disclosed |
| EP-2099784-A2 | 1,5-DIPHENYL-3-PYRIDINYLAMINO-1,5-DIHYDRIOYRROLIDIN-2-ONES AS CB1 RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2094684-A2 | 1,5-DIPHENYL-3-BENZYLAMINO-1,5-DIHYDROPYRROLIDIN 2-ONES AS CB1 RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008070305-A2 | 1, 5-DIPHENYL-3-PYRIDINYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CBL' RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070305-A2 | 1, 5-DIPHENYL-3-PYRIDINYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CBL' RECEPTOR MODULATOR | ELI LILLY AND COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070306-A2 | 1,5-DIPHENYL-3-BENZYLAMIN0-1,5-DIHYDR0PYRR0LIDIN-2-0NE AS CB1 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070306-A2 | 1,5-DIPHENYL-3-BENZYLAMIN0-1,5-DIHYDR0PYRR0LIDIN-2-0NE AS CB1 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | CA12 3793/4885CA1 3413/4885CA2 2182/4885 |
| US-20090275618-A1 | 1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR55 | CA12 4560/4885CA1 3412/4885CA2 3985/4885 |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | REN, ATP6V1B1, GLS | CA12 4794/4885CA1 4867/4885CA2 4613/4885 |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | DDT, TST, SCLY | CA12 4305/4885CA1 2366/4885CA2 1839/4885 |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | GSTA1, CYP1B1, DDT | CA12 3258/4885CA1 1091/4885CA2 1157/4885 |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | CA12 4871/4885CA1 4778/4885CA2 4343/4885 |
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | CA12 4794/4885CA1 4867/4885CA2 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.